2021
DOI: 10.4088/jcp.20m13699
|View full text |Cite
|
Sign up to set email alerts
|

The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
140
0
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 270 publications
(144 citation statements)
references
References 3 publications
3
140
0
1
Order By: Relevance
“…Our study focused on the entanglement of clinical variables and biochemical parameters in the occurrence of TRD in quite a large sample of patients hospitalized for MDD. In line with literature [37,41], TRD was present in slightly more than one-third (35.9%) of the recruited sample. In addition, with regard to rating scales, our sample showed scores that are reliable for inpatients with a diagnosis of MDD (HAM-D and MADRS mean total scores with standard deviations corresponding to a moderate-to-severe major depressive episode) [34,42].…”
Section: Discussionsupporting
confidence: 91%
“…Our study focused on the entanglement of clinical variables and biochemical parameters in the occurrence of TRD in quite a large sample of patients hospitalized for MDD. In line with literature [37,41], TRD was present in slightly more than one-third (35.9%) of the recruited sample. In addition, with regard to rating scales, our sample showed scores that are reliable for inpatients with a diagnosis of MDD (HAM-D and MADRS mean total scores with standard deviations corresponding to a moderate-to-severe major depressive episode) [34,42].…”
Section: Discussionsupporting
confidence: 91%
“…In Taiwan, 21% of patients treated for MDD were then classified as having TRD [32]. In the USA, 30.9% of treated MDD patients were classified as having TRD [24]. The much lower (8.3% in Hungary and 6.6% in the USA) as well as the much higher (55% in the UK) TRD prevalence reported in the literature can be explained by methodological differences in the inclusion criteria, the definition of TRD, or the source of the data [23,28,33].…”
Section: Trd Prevalencementioning
confidence: 99%
“…Total depression-related costs for TRD patients have been estimated to be 19 times higher than for other depressive patients [22]. In the USA, up to 47% of depression-associated costs are attributable to treatment resistance [2,24]. In Poland, the direct costs of depression exceed 1 billion PLN, while the indirect costs have been estimated at 1-2.6 billion PLN [25,26].…”
Section: Introductionmentioning
confidence: 99%
“…Given that ~20% of American adults suffer from a mental illness in a given year ( 256 ), the economic burden of these disorders is estimated to be in the hundreds of billions of dollars annually ( 257 , 258 ). Moreover, the current standard of care treatments suffer from slow onset (e.g., 7 week average response time with citalopram) ( 259 ), low efficacy (only 27% of depressed patients achieved remission after 12 weeks of citalopram treatment as measured by HAM-D) ( 259 ), and often intolerable side-effects ( 260 ), it is clear that we need to expand psychiatry's arsenal to include a variety of new approaches.…”
Section: Introductionmentioning
confidence: 99%
“…Moreover, all the therapists who participate in the psilocybin and MDMA clinical development programs are required to hold a professional license and demonstrate clinical experience in psychotherapy or mental health counseling ( 288 ). Although institutes such as the California Institute of Integral Study (CIIS), Multidisciplinary Association for Psychedelic Studies (MAPS), and corporate programs from companies like COMPASS Pathways offer short-term training programs for psychedelic-assisted counseling, there is a huge demand and supply gap for competent therapists considering that the estimated prevalence of treatment-resistant depression (TRD) in the U.S. is around 2.8 million people ( 258 ). Moreover, given that set and setting are well-known to influence the subjective effects of psychedelics ( 288 , 297 ), clinical centers with appropriate facilities will need to be established.…”
Section: Introductionmentioning
confidence: 99%